Physician | Interests: Heme Malignancies •BMT •Cellular therapy •PallOnc | Views my own
Buffalo, NY
Joined July 2023
- Tweets168
- Following439
- Followers158
- Likes1K
Mulham Ombada, MD retweeted
Efficacy of Stem Cell Boost (SCB) for CAR-T-related hematologic toxicity in #RRMM-RWE from the US multiple myeloma immunotherapy consortium
rdcu.be/fa4XX
Fortunate to have played a small part in this tremendous effort by #CindyVarga 👏🙌🎆
#MMSM #Medtwitter @BloodCancerJnl
@thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133 #DorisHansen & many more
Mulham Ombada, MD retweeted
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor | Haematologica haematologica.org/article/vi… #leusm
Mulham Ombada, MD retweeted
Dr Sanders describes all the #heme tumor data for early #pallonc for patients with advanced blood #cancer for use in the @ASCO guidelines for our @PallOncCoP #supponc
@crisbergerot @Chaosdyna @rabrazzak @DarcyBurbage @mehndz @AGovindarajanMD @KathrynDeCarli @MOmbada1 @MazieTsangMD
Mulham Ombada, MD retweeted
Dr Sanders describes all the #solid tumor data for early #pallonc for patients with advanced #cancer for use in the @ASCO guidelines for our @PallOncCoP #supponc
@crisbergerot @Chaosdyna @rabrazzak @DarcyBurbage @mehndz @AGovindarajanMD @KathrynDeCarli @MOmbada1
Mulham Ombada, MD retweeted
Yes!! My favorite #pallonc must attend webinar! Love seeing our #tribe learn and grow together. Please join us! #supponc
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
@RichaThakurMD
@MonikaJ95971150
@AnnaLaVigneMD
@JordanDBauman
@RachelleBrick
@mchwistek
@EK_Drake
@osutcuoglu
@MartinsWelchMD
@BenWThompson
@aarsh_a_desai
@BenWThompson
@bosnjaksupport
@tomleblancMD
@ramsedhom
@BillyRosaPhD
@EnriqueSoto8
@ChrisRalphXmed
@CWoodrellMD
@ApprillNicole
@KadakiaKunal
@TamrynGray
@sachinkalemd
@rabrazzak
@ELM_Eckert
@OncologyOdyssey
@NickScelzi
@JananiA779
@NikolasNaleid
@GMassaMD
@JananiA779
@MayaGogtay
@FernandoDiazMD1
@doctor_nurse7
@langmannga
@AdmaneSonal
@RajivAgarwalMD
@gandhi_shipra
@annakenney_DO
@SiennaDurbin
Join us for our monthly #webinar this Thursday March 19th at 4p EST as Dr Justin Sanders reviews the @ASCO guideline on Palliative Care in Oncology. DM for a link or join our #listserv [email protected]
@realbowtiedoc
@DarcyBurbage
@Chaosdyna
@crisbergerot
@GretchenMcnally
Mulham Ombada, MD retweeted
What’s next in renal cell carcinoma?
From the Trials in Progress session at #ASCOGU2026, here are several ongoing RCC trials that caught my attention.
The pipeline includes HIF-2α combinations, bispecific antibodies, radiopharmaceuticals, and emerging ADCs.
Mulham Ombada, MD retweeted
🚨 New in Multiple Myeloma
FDA approves teclistamab + daratumumab hyaluronidase for relapsed / refractory multiple myeloma after ≥1 prior line (PI + IMiD).
This is based on MAJESTEC-3, showing a striking PFS benefit.
🧬 Trial design
Patients randomized to:
🔹 Teclistamab + Daratumumab SC
vs
🔹 Investigator choice
• Daratumumab + Pomalidomide + Dex (DPd)
• Daratumumab + Bortezomib + Dex (DVd)
📊 Key efficacy results
• Median PFS: Not reached vs 18.1 months
• HR 0.17 (p <0.0001)
• OS HR 0.46
Translation for clinic:
👉 Deep disease control with BCMA bispecific + anti-CD38 combination early in relapse.
⚠️ Important toxicity signals
• Cytokine release syndrome (CRS)
• ICANS
• Hypogammaglobulinemia
• Infections
Drug available via Tecvayli-Talvey REMS program.
💡 Takeaway
Bispecific antibodies are moving earlier in the treatment sequence and may reshape relapse therapy in myeloma.
#OncoTwitter #MedTwitter #MultipleMyeloma #HemeOnc
@OncoAlert @ASCO @myESMO
Mulham Ombada, MD retweeted
QoL vs Survival: Older Patient's Preference & Outcomes
◾️Priority: Extending survival (8.4%) vs Maintaining QoL (71.7%) vs Neutral (20.0%)
◾️No difference in survival, hospitalizations, or toxicities between groups
👉Dividing patients into "Survival" vs "QoL" groups is difficult—most hope for both. Since AEs directly dictate QoL, continuous communication and treatment adjustment are vital to honor each patient's true wishes.
🔗jamanetwork.com/journals/jam…
@JAMAOnc @OncoAlert
Mulham Ombada, MD retweeted
Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.
Now, a new form of highly sensitive CAR T cells aims to overcome one of the biggest barriers in solid tumor immunotherapies—the way solid tumors lack a single, widely shared surface target.
By engineering an ultra-sensitive receptor capable of detecting even the smallest amounts of the protein CD70, researchers report in Science they were able to eradicate kidney, ovarian, and pancreatic tumors in preclinical models.
The findings provide a potential strategy to treat a broad range of solid tumors. scim.ag/400e2WU
Mulham Ombada, MD retweeted
Join us next week! @PallOncCoP will be hosting Dr Mel Davis to review @CancerCareMASCC guidelines on #opioid conversion. ‼️High Yield‼️especially for #EarlyCareer and #Trainees
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
@RichaThakurMD
@MonikaJ95971150
@AnnaLaVigneMD
@JordanDBauman
@RachelleBrick
@finlay_esme
@mchwistek
@EK_Drake
@osutcuoglu
@MartinsWelchMD
@BenWThompson
@aarsh_a_desai
@BenWThompson
@bosnjaksupport
@tomleblancMD
@ramsedhom
@BillyRosaPhD
@EnriqueSoto8
@ChrisRalphXmed
@CWoodrellMD
@ApprillNicole
@KadakiaKunal
@TamrynGray
@sachinkalemd
@rabrazzak
@ELM_Eckert
@OncologyOdyssey
@NickScelzi
@JananiA779
@NikolasNaleid
@GMassaMD
@JananiA779
@MayaGogtay
@FernandoDiazMD1
@doctor_nurse7
@langmannga
@AdmaneSonal
@RajivAgarwalMD
@gandhi_shipra
@annakenney_DO
Countdown to our February meeting is on!! Join us next week for an educational session with Dr. Mel Davis. @CancerCareMASCC @MASCC_JSCC
@realbowtiedoc
@DarcyBurbage
@Linda_E_Carlson
@crisbergerot
@FionnualaCrowle
@ramsedhom
@RyanNipp
@anhbl9
@jillfeldman4
@CThompson_MD
Mulham Ombada, MD retweeted
My favorite community connection every month! So glad we are restarting. Join my co-champ 🏆 @crisbergerot and I as we set the stage for @PallOncCoP 25-26. An amazing lineup of speakers. Join us Sept 25th
@RyanNipp
@TamrynGray
@Linda_E_Carlson
@WilliamDale_MD
@GretchenMcnally
@BbaharK
@asfeen_ummul
@Chaosdyna
@mehndz
@KathrynDeCarli
@Cthompson_MD
@kbnewport
@imdat_eroglu
@BorisMartinezMD
@AdmaneSonal
@NatashaDhawanMD
@vyasabhinav2
@DanijelaJakovl9
@RichaThakurMD
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
@MonikaJ95971150
@AnnaLaVigneMD
@JordanDBauman
@RachelleBrick
@finlay_esme
@mchwistek
@EK_Drake
@osutcuoglu
@MartinsWelchMD
@BenWThompson
@aarsh_a_desai
Yes it's that time of year again! #PallOncCoP is launching its Webinar Kick Off event in 2 weeks Sept 25th 4-5p EST. DM for a link or send your email to [email protected] to be added to the listserv.
See you soon! #pallonc #supponc
@MazieTsangMD @DarcyBurbage @crisbergerot
Mulham Ombada, MD retweeted
I’m honored to be a @RoswellPark @BloodCancerUtd captain for Light the Night.
I strongly support BCU (formerly LLS) as they support our patients and families! If you can contribute, it goes to a great cause!
#lymsm #mmsm #leuksm #bmtsm
pages.lls.org/ltn/wcny/Buffa…
Mulham Ombada, MD retweeted
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet thelancet.com/journals/lance…
Mulham Ombada, MD retweeted
August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung cancer.
We’ve made meaningful progress, but there’s still a long way to go. Each patient, each study, each step forward brings us closer to better outcomes.
Let’s keep climbing. 🌍🫁 #LCSM #Oncology @LungCancerRx @YoungLungCancer @IASLC @EGFRResisters
Mulham Ombada, MD retweeted
Breast cancer care must not depend on geography or GDP.
A blueprint for equity, not just efficiency.
#CancerCare #GlobalOncology #BreastCancer #EquityInHealth #LMIC @ASCO @JCOGO_ASCO @OncoAlert @BreastCancerNow @AORTIC_AFRICA @nazik_hammad @SirohiBhawna @GlopesMd @runciecwc @tmprowell @myESMO @jamecancerdoc
doi.org/10.1200/GO-25-00168
Mulham Ombada, MD retweeted
Our final #video summary of the #Top10Tips paper for #hpm on #survonc published in @PalliativeMed_j
Presenting Tip 🔟 #hpm can educate 🎓 about #SurvOnc
@JananiA779
@MayaGogtay
@FernandoDiazMD1
@EunbeeChoIM
@doctor_nurse7
@langmannga
@AdmaneSonal
@RajivAgarwalMD
@gandhi_shipra
@annakenney_DO
@SiennaDurbin
@ComeBommier
@veladconmigo
@chefaleixomd
@EunbeeChoIM
@doctor_nurse7
@AliBliPCdoc
@SKCCSupportSvcs
@asfeen_ummul
@Aoibh_Conneely
@NrajShah
@webbaamy
@SimonNoahEtkind
@Miriamcolleran2
@conorwbuckley
@KeanYew83
@JorgeOct
@Mombada1
@MonikaJ95971150
@drtulsijose
@bosnjaksupport
@ChandrikhaC
@GretchenMcnally
@aarsh_a_desai
@IshwariaMD
@Mombada1
@anhbl9
@vyasabhinav2
@BenWThompson
@harryhan08
@SagireddySowmya
@AgovindarajanMD
@mdbrunocosta
@EsmirnaPrzR
@ShivaniMD
@Rea_Booker
@srkumarasena
Mulham Ombada, MD retweeted
Excellent @JCO_ASCO editorial by @SagarLonialMD @myelomaMD about CARTITUDE-1, with 5-yr PFS of 33% off all treatment in myeloma! 👏 for CAR-T.
Most thoughtful discussion of cure in #MMsm I’ve read… the MGUS-like MRD-positive phenotype 👇 needs to be part of the discussion!
A Cure, a Cure, My Kingdom for a Cure: patients with refractory myeloma can achieve long-term remissions following CAR-T therapy, earlier use may cure more. Thoughtful @JCO_ASCO commentary @SagarLonialMD
ascopubs.org/doi/full/10.120…
Mulham Ombada, MD retweeted
Maintaining our short #video summaries of the #Top10Tips paper for #hpm on #survonc published in
@PalliativeMed_j
Presenting Tip 3⃣ Late and long-term #tox 🤕
@DanijelaJakovl9
@RichaThakurMD
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
@MonikaJ95971150
@AnnaLaVigneMD
@JordanDBauman
@RachelleBrick
@finlay_esme
@mchwistek
@EK_Drake
@osutcuoglu
@MartinsWelchMD
@BenWThompson
@aarsh_a_desai
@annakenney_DO
@ChrisRalphXmed
@CWoodrellMD
@ApprillNicole
@KadakiaKunal
@TamrynGray
@sachinkalemd
@rabrazzak
@ELM_Eckert
@OncologyOdyssey
@NickScelzi
@JananiA779
@NikolasNaleid
@GMassaMD
@JananiA779
@MayaGogtay
@FernandoDiazMD1
Mulham Ombada, MD retweeted
Nothing gives me a boost like meeting with my @PallOncCoP family. Combine that with my love of #nerdy 🤓 and this is going to be a dynamite collaboration. Make sure you don't miss out next week. Join us! #hpm #hapc #pallonc #supponc #AI #healthIT
@DanijelaJakovl9
@RichaThakurMD
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
@MonikaJ95971150
@AnnaLaVigneMD
@AlawtonMD
@DittamiLisa
@JordanDBauman
@RachelleBrick
@finlay_esme
@mchwistek
@FionnualaCrowle
@EK_Drake
@osutcuoglu
@MartinsWelchMD
@BenWThompson
@aarsh_a_desai
@annakenney_DO
@Cthompson_MD
@ChrisRalphXmed
@CWoodrellMD
@ApprillNicole
@KadakiaKunal
@TamrynGray
@anhbl9
@sachinkalemd
@rabrazzak
@ELM_Eckert
@OncologyOdyssey
@NickScelzi
@crisbergerot
@JananiA779
@drtulsijose
@NikolasNaleid
@IshwariaMD
@GMassaMD
@JananiA779
@MayaGogtay
@FernandoDiazMD1
@EunbeeChoIM
@doctor_nurse7
@langmannga
Join us April 29th 4p EST as we join #AICoP co-champs @ravi_b_parikh and @ca_chung to discuss #AI 🤖 in #SuppOnc with global impact 🌎 DM for meeting link or to be added to our mailing list
@realbowtiedoc
@MazieTsangMD
@crisbergerot
@FionnualaCrowle
@anhbl9
@ramsedhom
Mulham Ombada, MD retweeted
#Myeloma Paper of the Day: Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory myeloma achieve higher response rates (100% in 52 pts) vs. other options & increase clonality in the CD4+ and CD8+ T cell post_CAR T: pubmed.ncbi.nlm.nih.gov/3944…. #mmsm
